GlassScriptPhysician profile
Youssry Kelada
NPI 1316919442
$12,151.39
in general payments reported to CMS, 2019-2025
50 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,705 · 2020: $2,066 · 2021: $3,019 · 2022: $2,255 · 2023: $1,537 · 2024: $427 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,584.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,083.16 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $999.26 | 2019-2023 | Jardiance, Ofev |
| Abbvie INC. | $910.14 | 2020-2024 | |
| Astellas Pharma US INC | $782.34 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $591.62 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $576.88 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $540.11 | 2019-2024 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $492.64 | 2021-2024 | |
| Lilly USA, LLC | $488.52 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $484.38 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $478.21 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Amarin Pharma, INC. | $288.91 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.44 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $252.63 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssry Kelada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.